The ASN Board Review Course & Update (BRCU) is the primary preparatory course for the ABIM's initial certification and maintenance of certification examinations in nephrology and is the premier comprehensive update for the practicing nephrologist. Each BRCU topic section and its applicable time allocation are patterned after the ABIM nephrology examination blueprint. Lectures, interactive case discussions, and panel discussions are integral parts of the BRCU program. Relevant physiology and pathophysiology are blended with clinical discussions aimed at reviewing, updating, and preparing for the Board Certification and MOC Examinations.
ASN is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Upon completion of the online attestation and evaluation, CME credit will be posted to your ASN transcript within two to three weeks. Access your ASN Official Transcript.
On the CME site, you can also take the ASN BRCU practice final examination. Your score, as well as the correct answers and explanations can be printed out upon completion of the examination.
Upon completion of this course the participant will be able to 1) integrate basic and clinical considerations in the management of patients with kidney disease, 2) apply key concepts and techniques to the treatment of patients with kidney disease, and 3) translate the results of case studies into practical strategies to improve patient care.
Internationally renowned speakers were selected for their expert teaching skills and highly rated past performances in this and similar courses. Included in this esteemed faculty are current and former ASN Presidents and Councilors and former members of the ABIM Subspecialty Board on Nephrology.
Faculty Listing/Disclosures
Zalman S. Agus, MD
University of Pennsylvania
Philadelphia, PA
Disclosure: Nothing to Disclose
Gerald B. Appel, MD, FASN
Columbia University College of Physicians and Surgeons
New York, NY
Disclosure: Grants: Aspreva-Viofor, Genentech; Consultant: Aspreva-Viofor, Genentech, Merck, Pfizer, Astra-Zeneca, Forrest Labs, Genzyme, Amgen, Ortho, Bristol-Myers-Squib; Honoraria: Genzyme, Merck, Pfizer, Astra-Zeneca, Ortho, Amgen, Abbott.
George R. Aronoff, MD
University of Louisville Kidney Disease Program
Louisville, KY
Disclosure: Grants: Merck, Inc, NxStage, NIH, Guerbet; Consultant: Fresenius, Merck, Affymax; Advisor: Merck, Inc, AMAG; Honoraria: Novartis, Fresenius.
Phyllis August, MD
Weill Medical College of Cornell University
New York, NY
Disclosure: Nothing to Disclose
William M. Bennett, MD, FASN
Legacy Good Samaritan Hospital
Portland, OR
Disclosure:Grants: Astellas Pharmaceuticals, Otsuka Pharmaceuticals.
Tomas Berl, MD, FASN
University of Colorado Health Services Center
Denver, CO
Disclosure: Consultant: Otsuka, Astellas; Honoraria: Otsuka, Astellas.
Jeffrey S. Berns, MD, FASN
University of Pennsylvania School of Medicine
Philadelphia, PA
Disclosure: Nothing to Disclose
BRCU Education Director
John M. Burkart, MD
Wake Forest University Baptist Medical Center
Winston-Salem, NC
Disclosure: Grants: Baxter, Nxstage, Genzyme, Abbott, Watson, AMAG, Amgen, Fresenius; Advisor: Baxter, Nxstage; Honoraria: Baxter, Genzyme, Fresenius; Current Employer: Wake Forest University and Health Systems Management.
David A. Bushinsky, MD
University of Rochester Medical Center
Rochester, NY
Disclosure:Grants: NIH, Renal Research Institute; Consultant: Amgen, Genzyme, Shire, Cytochroma, Relypsa; Advisor: Amgen, Genzyme, Shire, Cytochroma, Relypsa; Honoraria: Amgen, Genzyme, Shire, Cytochroma, Relypsa.
Stuart Cohen, MD
University of California, Davis
Sacramento, CA
Disclosure: Nothing to Disclose
William G. Couser, MD, FASN
University of Washington
Seattle, WA
Disclosure: Consultant: Questcor; Honoraria: Questcor.
Laura M. Dember, MD, FASN
Boston University School of Medicine
Boston, MA
Disclosure:Grants: Proteon Therapeutics; Consultant: Bristol-Myers Squibb; Advisor: Proteon Therapeutics.
Thomas A. Depner, MD
University of California Davis
Sacramento, CA
Disclosure: Nothing to Disclose
Thomas D. DuBose, Jr., MD, FASN
Wake Forest University School of Medicine
Winston-Salem, NC
Disclosure: Consultant: Heparin Scientific; Relypsa.
Chair, Education Committee
Ronald J. Falk, MD, FASN
University of North Carolina Kidney Center
Chapel Hill, NC
Disclosure: Nothing to Disclose
Agnes B. Fogo, MD
Vanderbuilt University Medical Center
Nashville, TN
Disclosure: Nothing to Disclose
Richard J. Glassock, MD
David Geffen School of Medicine at UCLA
Los Angeles, CA
Disclosure: Consultant: Aspreva, Novartis, Genentech, Gilead Sciences, QuestCor, FibroGen, UpToDate, American Society of Nephrology.
Stanley Goldfarb, MD, FASN
University of Pennsylvania School of Medicine
Philadelphia, PA
Disclosure: Consultant: GE Healthcare, Fresenius, Abbott.
L. Lee Hamm, MD
Tulane University School of Medicine
New Orleans, LA
Disclosure: Nothing to Disclose
William L. Henrich, MD, FASN
University of Texas Health Science Center at San Antonio
San Antonio, TX
Disclosure: Nothing to Disclose
L. Tammy Ho, MD
Evanston Hospital
Evanston, IL
Disclosure: Nothing to Disclose
Donald E. Hricik, MD
University Hospitals of Cleveland
Cleveland, OH
Disclosure: Nothing to Disclose
Warren L. Kupin, MD
University of Miami School of Medicine
Miami, FL
Disclosure: Nothing to Disclose
Sharon M. Moe, MD, FASN
Indiana University School of Medicine
Indianapolis, IN
Disclosure: Grants: Amgen, Genzyme, Shire; Consultant: Amgen, Genzyme, Shire, DiaSorin, Ineos, Litholink; Honoraria: Amgen, Genzyme, Shire, DiaSorin, Ineos, Litholink.
Bruce A. Molitoris, MD
Indiana University
Indianapolis, IN
Disclosure: Grants: NIH, VA, Quark Pharma., Eil Lilly Pharma., Fast Diagnostics Inc.; Consultant: Eli Lilly, Quark, Astra Zeneca; Advisor: Medical Director for FAST Diagnostics; Ownership: FAST Diagnostics; Patent and Invention: Indiana University, FAST Diagnostics, Eli Lilly; Current Employer: Indiana University, VA.
Douglas J. Norman, MD
Oregon Health and Science University
Portland, OR
Disclosure: Nothing to Disclose
Jean L. Olson, MD
University of California, San Francisco
San Francisco, CA
Disclosure: Nothing to Disclose
Paul M. Palevsky, MD, FASN
University of Pittsburgh School of Medicine
Pittsburgh, PA
Disclosure: Nothing to Disclose
Biff F. Palmer, MD, FASN
University of Texas Southwestern Medical Center
Dallas, TX
Disclosure: Nothing to Disclose
Beth M. Piraino, MD
University of Pittsburgh
Pittsburgh, PA
Disclosure: Nothing to Disclose
BRCU Education Director
Marc A. Pohl, MD
The Cleveland Clinic
Cleveland, OH
Disclosure: Advisor: Collaborative Study Group Executive Committee.
Jai Radhakrishnan, MD, FASN
New York Pesbyterian Hospital
New York, NY
Disclosure: Advisor: Genentech Scientific Advisory Board.
Helmut G. Rennke, MD
Brigham and Women's Hospital
Boston, MA
Disclosure: Nothing to Disclose
Richard H. Sterns, MD
Rochester General Hospital
Rochester, NY
Disclosure: Consultant: Astellas, Otsuka; Honoraria: Astellas, Otsuka.
John B. Stokes, III, MD, FASN
University of Iowa
Iowa City, IA
Disclosure: Nothing to Disclose
Marshall L. Stoller, MD
University of California San Francisco
San Francisco, CA
Disclosure: Nothing to Disclose
Lynda A. Szczech, MD, FASN
Duke University Medical Center
Durham, NC
Disclosure: Nothing to Disclose
Stephen J. Tomlanovich, MD
University of California San Francisco
San Francisco, CA
Disclosure: Nothing to Disclose
Raymond R. Townsend, MD
University of Pennsylvania Health System
Philadelphia, PA
Disclosure: Grants: NIH, Novartis; Consultant: Roche, GSK, SPacelabs, Nicox; Advisor: Takeda; Honoraria: Merck, ASH, ACP, PIER, ASN; Royalties: UpToDate.
Jerry Yee, MD, FASN
Henry Ford Hospital
Detroit, MI
Disclosure: Grants: Amgen; Consultant: Amgen, Merck, Pericor, Watson, AMAG; Advisor: National Kidney Foundation; Honoraria: Genzyme, Merck, Amgen, AMAG, Watson; Ownership: Amgen, Merck; Patent and Invention: Henry Ford Hospital: dialysis surveillance and anemia management software; Current Employer: Henry Ford Health System; Other: National Kidney Foundation: Editor-in-Chief, Advances in Chronic Kidney Disease.
It is the policy of ASN that all individuals in a position to control the content of ASN's sponsored CME activities are expected to provide full disclosure for both themselves and their spouse/partner, and indicate to the activity audience any financial or other relationship held by themselves or their spouse/partner 1) with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial service(s) discussed in an educational presentation; and 2) with any commercial supporter(s) of the activity. All responses should reflect activities within the last 12 months. The intent of this disclosure is to provide attendees with disclosure information prior to participation in the educational activity, in accordance with Accreditation Council for Continuing Medical Education (ACCME) and American Medical Association (AMA) Physician's Recognition Award (PRA) guidelines. Further, ASN requires all faculty to disclose any planned discussion of investigational and/or off-label use of pharmaceutical products or devices within their presentation. Participants should note that the use of products outside Federal Drug Administration-approved labeling should be considered experimental and are advised to consult current prescribing information for approval indications. There may be discussion of unapproved or off-label use of product(s) during the presentations.
The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from involvement in Continuing Medical Education (CME), but rather to ensure that ASN CME activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. In addition, all faculty members were instructed to provide balanced, scientifically rigorous, and evidence-based presentations.
As a condition of your access and use of the Website, you agree not to use the Website for any purpose that is unlawful or inconsistent with the Agreement. ASN, in its sole discretion, is authorized to remove or delete any entries, information, materials, or other content that violates these Terms of Use or that is otherwise objectionable. ASN reserves the right to investigate and prosecute violations of any of these Terms of Use to the fullest extent of the law. If Users fail to comply with these Terms of Use, ASN in its sole discretion may terminate the User's access to the website immediately without advance notice. These terms of use comprise an Agreement that is governed by the laws of the District of Columbia, which shall be the forum for any disputes.
All sales are final.
If you previously completed and received credit for the live CME activity, ASN 14th Annual Board Review Course and Update, please note that you will not receive credit for completing this activity.
The Board Review Course & Update 2009 live activity was supported by educational grants from the following companies:
Amgen, Genzyme, Merck & Co., Inc., Otsuka America Pharmaceutical, Inc., and Questcor Pharmaceuticals, Inc.
The BRCU 2009 online enduring material is not commercially supported.
For any questions concerning this activity, please contact ASN at 202-659-0599 or via email to email@asn-online.org.